BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rasche L, Röllig C, Stuhler G, Danhof S, Mielke S, Grigoleit GU, Dissen L, Schemmel L, Middeke JM, Rücker V, Schreder M, Schetelig J, Bornhäuser M, Einsele H, Thiede C, Knop S. Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Focus on Longitudinal Assessment of Donor Chimerism, Extramedullary Disease, and High-Risk Cytogenetic Features. Biol Blood Marrow Transplant 2016;22:1988-96. [PMID: 27590108 DOI: 10.1016/j.bbmt.2016.08.024] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.8] [Reference Citation Analysis]
Number Citing Articles
1 Eefting M, de Wreede LC, Von dem Borne PA, Halkes CJM, Kersting S, Marijt EWA, Putter H, Veelken H, Schetelig J, Falkenburg JHF. Donor T-cell responses and disease progression patterns of multiple myeloma. Bone Marrow Transplant 2017;52:1609-15. [PMID: 28967897 DOI: 10.1038/bmt.2017.201] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
2 Ikeda T, Mori K, Kawamura K, Mori T, Hagiwara S, Ueda Y, Kahata K, Uchida N, Tsukada N, Murakami S, Yamamoto M, Takahashi T, Ichinohe T, Onizuka M, Atsuta Y, Kanda Y, Okamoto S, Sunami K, Takamatsu H. Comparison between autologous and allogeneic stem cell transplantation as salvage therapy for multiple myeloma relapsing/progressing after autologous stem cell transplantation. Hematological Oncology 2019;37:586-94. [DOI: 10.1002/hon.2688] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
3 Zhou X, Einsele H, Danhof S. Bispecific Antibodies: A New Era of Treatment for Multiple Myeloma. J Clin Med 2020;9:E2166. [PMID: 32659909 DOI: 10.3390/jcm9072166] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
4 Tyler J, Kumer L, Fisher C, Casey H, Shike H. Personalized Chimerism Test that Uses Selection of Short Tandem Repeat or Quantitative PCR Depending on Patient's Chimerism Status. The Journal of Molecular Diagnostics 2019;21:483-90. [DOI: 10.1016/j.jmoldx.2019.01.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
5 Holstein SA, Suman VJ, Owzar K, Santo K, Benson DM Jr, Shea TC, Martin T, Silverman M, Isola L, Vij R, Cheson BD, Linker C, Anderson KC, Richardson PG, McCarthy PL. Long-Term Follow-up of CALGB (Alliance) 100001: Autologous Followed by Nonmyeloablative Allogeneic Transplant for Multiple Myeloma. Biol Blood Marrow Transplant 2020;26:1414-24. [PMID: 32325171 DOI: 10.1016/j.bbmt.2020.03.028] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Rasche L, Kortüm KM, Raab MS, Weinhold N. The Impact of Tumor Heterogeneity on Diagnostics and Novel Therapeutic Strategies in Multiple Myeloma. Int J Mol Sci 2019;20:E1248. [PMID: 30871078 DOI: 10.3390/ijms20051248] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 8.7] [Reference Citation Analysis]
7 Novak P, Klyuchnikov E, von Pein UM, Güllstorf M, Christopeit M, Ayuk F, Geffken M, Wolschke C, Kröger N. Second allogeneic stem cell transplantation for relapse after allografting in multiple myeloma using CD 34+ selected donor cells without immunosuppression. Bone Marrow Transplant 2020;55:1817-20. [PMID: 32350376 DOI: 10.1038/s41409-020-0912-7] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Green DJ, Bensinger WI. A View from the Plateau: Is There a Role for Allogeneic Stem Cell Transplantation in the Era of Highly Effective Therapies for Multiple Myeloma? Curr Hematol Malig Rep 2017;12:61-7. [PMID: 28144893 DOI: 10.1007/s11899-017-0365-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
9 Malek E, El-Jurdi N, Kröger N, de Lima M. Allograft for Myeloma: Examining Pieces of the Jigsaw Puzzle. Front Oncol 2017;7:287. [PMID: 29322027 DOI: 10.3389/fonc.2017.00287] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
10 Chen Y, Tao S, Zheng X, Shi Y, Zhang L, Chen K, He Z, Wang C, Yu L. Research progress on treatment of extramedullary multiple myeloma. Hematology 2021;26:985-94. [PMID: 34871523 DOI: 10.1080/16078454.2021.2005310] [Reference Citation Analysis]
11 Gahrton G, Iacobelli S, Garderet L, Yakoub-Agha I, Schönland S. Allogeneic Transplantation in Multiple Myeloma-Does It Still Have a Place? J Clin Med 2020;9:E2180. [PMID: 32664274 DOI: 10.3390/jcm9072180] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
12 Greil C, Engelhardt M, Ihorst G, Schoeller K, Bertz H, Marks R, Zeiser R, Duyster J, Einsele H, Finke J, Wäsch R. Allogeneic transplantation of multiple myeloma patients may allow long-term survival in carefully selected patients with acceptable toxicity and preserved quality of life. Haematologica 2019;104:370-9. [PMID: 30237266 DOI: 10.3324/haematol.2018.200881] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 8.0] [Reference Citation Analysis]
13 Bansal R, Rakshit S, Kumar S. Extramedullary disease in multiple myeloma. Blood Cancer J 2021;11:161. [PMID: 34588423 DOI: 10.1038/s41408-021-00527-y] [Reference Citation Analysis]
14 Xu J, Yu N, Zhao P, Wang F, Huang J, Cui Y, Ding H, Yang Y, Gao Y, Pan L, Chang H, Wu Y, Xiang B, Gong Y, Shuai X, Hou L, Xie L, Niu T, Liu T, Zhang L, Liu W, Zhang W, Qu Y, Lin W, Zhu Y, Zhao S, Zheng Y. Intratumor Heterogeneity of MIF Expression Correlates With Extramedullary Involvement of Multiple Myeloma. Front Oncol 2021;11:694331. [PMID: 34268123 DOI: 10.3389/fonc.2021.694331] [Reference Citation Analysis]
15 Caballero-Velázquez T, Calderón-Cabrera C, López-Corral L, Puig N, Marquez-Malaver F, Pérez-López E, García-Calderón C, Rosso-Fernández CM, Caballero Barrigón D, Martín J, Mateos MV, San Miguel J, Pérez-Simón JA; European Myeloma Network. Efficacy of bortezomib to intensify the conditioning regimen and the graft-versus-host disease prophylaxis for high-risk myeloma patients undergoing transplantation. Bone Marrow Transplant 2020;55:419-30. [PMID: 31551517 DOI: 10.1038/s41409-019-0670-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
16 Luoma S, Silvennoinen R, Rauhala A, Niittyvuopio R, Martelin E, Lindström V, Heiskanen J, Volin L, Ruutu T, Nihtinen A. Long-term outcome after allogeneic stem cell transplantation in multiple myeloma. Ann Hematol 2021;100:1553-67. [PMID: 33866396 DOI: 10.1007/s00277-021-04514-y] [Reference Citation Analysis]
17 Nikolaenko L, Chhabra S, Biran N, Chowdhury A, Hari PN, Krishnan A, Richter J. Graft-Versus-Host Disease in Multiple Myeloma Patients Treated With Daratumumab After Allogeneic Transplantation. Clinical Lymphoma Myeloma and Leukemia 2020;20:407-14. [DOI: 10.1016/j.clml.2020.01.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
18 Gagelmann N, Eikema DJ, Koster L, Caillot D, Pioltelli P, Lleonart JB, Reményi P, Blaise D, Schaap N, Trneny M, Passweg J, Porras RP, Cahn JY, Musso M, Poiré X, Fenk R, Itälä-Remes M, Pavone V, Fouillard L, Maertens J, Bron D, Pouli A, Schroyens W, Schönland S, Garderet L, Yakoub-Agha I, Kröger N. Tandem Autologous Stem Cell Transplantation Improves Outcomes in Newly Diagnosed Multiple Myeloma with Extramedullary Disease and High-Risk Cytogenetics: A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2019;25:2134-42. [PMID: 31288095 DOI: 10.1016/j.bbmt.2019.07.004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
19 Chhabra S, Szabo A, Glisch C, George G, Narra RK, Harrington A, Jerkins JH, D'Souza A, Dhakal B, Pasquini MC, Hamadani M, Hari PN. Relapse after Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma: Survival Outcomes and Factors Influencing Them. Biol Blood Marrow Transplant 2020;26:1288-97. [PMID: 32135202 DOI: 10.1016/j.bbmt.2020.02.020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
20 Maffini E, Storer BE, Sandmaier BM, Bruno B, Sahebi F, Shizuru JA, Chauncey TR, Hari P, Lange T, Pulsipher MA, McSweeney PA, Holmberg L, Becker PS, Green DJ, Mielcarek M, Maloney DG, Storb R. Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma. Haematologica 2019;104:380-91. [PMID: 30262560 DOI: 10.3324/haematol.2018.200253] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
21 Zhou X, Flüchter P, Nickel K, Meckel K, Messerschmidt J, Böckle D, Knorz S, Steinhardt MJ, Krummenast F, Danhof S, Einsele H, Kortüm KM, Rasche L. Carfilzomib Based Treatment Strategies in the Management of Relapsed/Refractory Multiple Myeloma with Extramedullary Disease. Cancers (Basel) 2020;12:E1035. [PMID: 32340174 DOI: 10.3390/cancers12041035] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
22 Franch-Sarto M, Anglada Escalona JR, Tuset Beltran V, Ribera Santasusana JM, Ferrà Coll C. A unique case of relapse of plasma cell leukemia in the vitreous humor. Leuk Res 2020;93:106357. [PMID: 32353698 DOI: 10.1016/j.leukres.2020.106357] [Reference Citation Analysis]
23 Gomez-Arteaga A, Shah GL, Baser RE, Scordo M, Ruiz JD, Bryant A, Dahi PB, Ghosh A, Lahoud OB, Landau HJ, Landgren O, Shaffer BC, Smith EL, Koehne G, Perales MA, Giralt SA, Chung DJ. Prognostic Factors for Postrelapse Survival after ex Vivo CD34+-Selected (T Cell-Depleted) Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma. Biol Blood Marrow Transplant 2020;26:2040-6. [PMID: 32712326 DOI: 10.1016/j.bbmt.2020.07.016] [Reference Citation Analysis]
24 Vincent L, Gras L, Ceballos P, Finke J, Passweg J, Harel S, Rosinol L, Minnema M, Teipel R, van Doesum J, Hänel M, Lenain P, Botella-Garcia C, Koenecke C, Ducastelle S, Sanz J, Schroyens W, Zuckerman T, Monaco F, Koster L, de Wreede L, Hayden PJ, Schönland S, Yakoub-Agha I, Beksac M. Daratumumab after allogeneic hematopoietic cell transplantation for multiple myeloma is safe and synergies with pre-existing chronic graft versus host disease. A retrospective study from the CMWP EBMT. Bone Marrow Transplant 2022. [PMID: 35013536 DOI: 10.1038/s41409-021-01560-y] [Reference Citation Analysis]
25 Green DJ, Maloney DG, Storer BE, Sandmaier BM, Holmberg LA, Becker PS, Fang M, Martin PJ, Georges GE, Bouvier ME, Storb R, Mielcarek M. Tandem autologous/allogeneic hematopoietic cell transplantation with bortezomib maintenance therapy for high-risk myeloma. Blood Adv 2017;1:2247-56. [PMID: 29296873 DOI: 10.1182/bloodadvances.2017010686] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
26 Markovic U, Calafiore V, Martino E, Giubbolini R, Parisi MS, Romano A, Del Fabro V, Di Raimondo F, Conticello C. A rare case of multiple myeloma with intracranial extramedullary relapse: One or more myeloma clones? Clin Case Rep 2019;7:1629-36. [PMID: 31534716 DOI: 10.1002/ccr3.2292] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
27 Rasche L, Weinhold N, Morgan GJ, van Rhee F, Davies FE. Immunologic approaches for the treatment of multiple myeloma. Cancer Treat Rev 2017;55:190-9. [PMID: 28431262 DOI: 10.1016/j.ctrv.2017.03.010] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 4.6] [Reference Citation Analysis]
28 Richter J, Ramasamy K, Rasche L, Bladé J, Zweegman S, Davies F, Dimopoulos M. Management of patients with difficult-to-treat multiple myeloma. Future Oncol 2021;17:2089-105. [PMID: 33706558 DOI: 10.2217/fon-2020-1280] [Reference Citation Analysis]
29 Danhof S, Rasche L, Mottok A, Steinmüller T, Zhou X, Schreder M, Kilian T, Strifler S, Rosenwald A, Hudecek M, Einsele H, Gerhard-Hartmann E. Elotuzumab for the treatment of extramedullary myeloma: a retrospective analysis of clinical efficacy and SLAMF7 expression patterns. Ann Hematol 2021;100:1537-46. [PMID: 33575947 DOI: 10.1007/s00277-021-04447-6] [Reference Citation Analysis]
30 Eisfeld C, Eßeling E, Wullenkord R, Khandanpour C, Reusch J, Mikesch JH, Reicherts C, Kerkhoff A, Schliemann C, Kessler T, Mesters RM, Berdel WE, Lenz G, Stelljes M. Long-term survival and polyclonal immunoglobulin reconstitution after allogeneic stem cell transplantation in multiple myeloma. Ann Hematol 2020;99:1907-15. [PMID: 32444892 DOI: 10.1007/s00277-020-04068-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]